Novo Nordisk Just Killed Part of Its Biggest Obesity Drug. Here's Why That's Good News.

But it ran into a wall when tested head-to-head against Eli Lilly's tirzepatide (sold as Zepbound). In the REDEFINE 4 trial over 84 weeks, CagriSema delivered 20.2% weight loss under real-world conditions, compared to 23.6% for Zepbound. It failed to prove non-inferiority, which is pharma-speak for "we couldn't even show we were roughly as good."

That result slashed analyst sales forecasts from 85 billion Danish kroner to 50 billion by 2035. One analyst called it an "unforced error."

So why is Novo still charging ahead? Because CagriSema doesn't need to beat Zepbound. It needs to beat semaglutide, and it does that convincingly. In patients with type 2 diabetes (the REIMAGINE 2 trial), CagriSema hit 14.2% weight loss versus 10.2% for semaglutide 2.4 mg. It also showed superior blood sugar control: a 1.91% reduction in HbA1c versus 1.76%.

A Crowded Starting Line

The obesity drug market in 2026 looks like a Formula 1 grid with too many cars. Eli Lilly has retatrutide (a triple agonist hitting up to 28.7% weight loss in trials) approaching an FDA decision. Amgen's MariTide offers monthly dosing instead of weekly. Novo's own oral amycretin is in early trials. And Novo just launched oral Wegovy at $149 per month, undercutting its own injectable.

CagriSema's FDA application was filed in December 2025, with a decision expected late 2026. The drug would enter a market where patients and doctors have more choices than ever. Novo's pitch: this is a different mechanism (GLP-1 plus amylin, not GLP-1 plus GIP), it's a once-weekly injection they already know how to give, and the weight loss exceeds anything semaglutide alone can deliver.

The device decision actually strengthens that pitch. A dual-chamber pen is more complex to manufacture, sure. But it's the pen that generated all the Phase 3 data, the one the FDA is reviewing, and the one Novo already knows how to make. No bridging studies needed. No bioequivalence questions to answer.

Simplify to Survive

This is the kind of unsexy decision that wins races. Novo could have spent another two or three years perfecting a single-chamber formulation, running equivalence studies, and hoping the simpler pen would eventually reduce manufacturing costs. That's a "nice to have" optimization for 2029 or 2030.

What Novo needs right now is to get CagriSema approved and on the market before the competitive window closes. Every month of delay is a month where Zepbound, retatrutide, and MariTide eat into its addressable market.

The dual-chamber pen is more expensive to produce, and it requires more patient training. But those are problems for a drug that's already selling. You can't optimize the manufacturing of a product that hasn't launched yet.

The Bottom Line

Novo Nordisk chose speed over elegance. In the current obesity drug arms race, where three to four major FDA decisions are expected in the first half of 2026 alone, that's probably the right call. The single-chamber pen was always a long-term manufacturing play; ditching it removes uncertainty without sacrificing a single day on the launch calendar.

CagriSema doesn't need a prettier pen. It needs an approval date. And with the FDA decision expected later this year, Novo just cleared one more hurdle off the track.

Madrigal's Billion-Dollar Bet on Silencing Genes

Madrigal Pharmaceuticals just paid up to $1 billion for a gene-silencing drug to pair with its blockbuster MASH therapy Rezdiffra. It's the third major deal in a year as the company races to build an unbeatable liver disease franchise before Novo Nordisk and others crash the party.